Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively expanding its product offerings in the CAR-T cell therapy and recombinant protein sectors, benefiting from the depreciation of the RMB and recognition as a "specialized and innovative" enterprise [2][3][4]. Group 1: Company Developments - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product range related to cell and gene therapy [2]. - The company has developed high-quality recombinant proteins through its proprietary biotechnology platform, addressing various disease targets and biomarkers [2]. - The company is developing products related to monkeypox virus, including recombinant proteins and test kits, to support vaccine and therapeutic drug development [2]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit of 132 million yuan, up 58.61% year-on-year [9]. - The company's overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. Group 3: Market Position and Recognition - The company has been recognized as a "national-level specialized and innovative small giant enterprise," indicating its strong market position, innovation capabilities, and high market share [3]. - The company operates in the pharmaceutical and biotechnology sector, focusing on recombinant proteins and other biological products, with a significant portion of its revenue derived from these areas [8][9].
百普赛斯涨1.96%，成交额1.60亿元，近5日主力净流入2940.43万